2016年7月， 温州医科大学附属第一医院 在OncoTargets and Therapy（IF2.7 / 4区）上在线发表了一篇论文。在 发表9年后 ，因 图片组内重复 在pubpeer上被读者质疑。

Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee: Brisbane, California Saturday, April 5, 2 ...

The following is a summary of “Intrathecal interleukin-6 levels are associated with progressive disease and clinical severity ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

Could interleukin-1 antagonists be the answer to managing acute gout? Guidelines for the management of this disorder, issued by the European League Against Rheumatism (EULAR) and the British ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Low dose interleukin 2 is being tested as an immunomodulatory approach in neurodegenerative diseases. It increases the number and activity of regulatory T cells (Tregs) that suppress inflammation. At ...

Researchers from Charité - Universitätsmedizin Berlin and the Max Delbrück Center have identified the precise mechanism by ...

T helper 17 (Th17) cells generate the pro-inflammatory cytokine interleukin-17 (IL17/IL17A). IL17 has been a target for a variety of therapeutic monoclonal antibodies and inhibitors to treat ...

BioSciences announced the first patient has been dosed in the Phase 2 ASCEND study of PCRX-201 for the treatment of ...

The following is a summary of “Trans-omics landscape of systemic vasculitis identified matrix metalloproteinase 12 as a novel ...